Immunovia
1,64 SEK +0,49%Vær den første som følger denne virksomhed
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
IMMNOV
Daglig lav / høj pris
1,6 / 1,778
SEK
Markedsværdi
74,27 mio. SEK
Aktieomsætning
730,08 t SEK
Volumen
441 t
Seneste videoer
Finanskalender
Delårsrapport
22.08.2024
Delårsrapport
14.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Försäkringsbolaget Avanza Pension | 9,9 % | 9,9 % |
Carl Borrebaeck | 3,8 % | 3,8 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Immunovia AB: Immunovia's new lab staffed and operational after rapid implementation
Immunovia AB: BULLETIN FROM THE ANNUAL GENERAL MEETING ON 19 JUNE 2024 IN IMMUNOVIA AB (PUBL)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools